Cullinan Therapeutics, Inc. CGEM Total debt

Total debt at other companies

Eli LillyLLY

$54.91B+37.6%

Johnson & JohnsonJNJ

$49.04B-3.4%

AmgenAMGN

$57.3B+2.0%

Regeneron PharmaceuticalsREGN

$2.71B+0.1%

Vor BiopharmaVOR

$2.94M-90.5%

Climb Bio, Inc.CLYM

$479K+1.1%

FAQ

What is Cullinan Therapeutics, Inc.'s total debt?

Cullinan Therapeutics, Inc. (CGEM) reported total debt of $2.07M in Q2 2026.

How has Cullinan Therapeutics, Inc.'s total debt changed year-over-year?

Cullinan Therapeutics, Inc.'s total debt increased by 36.3% year-over-year, from $1.52M to $2.07M.

What is the long-term trend for Cullinan Therapeutics, Inc.'s total debt?

Over 4 years (2021 to 2025), Cullinan Therapeutics, Inc.'s total debt has grown at a 18.2% compound annual growth rate (CAGR), from $1.38M to $2.68M.

What does total debt mean?

Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.